Skip to search formSkip to main contentSkip to account menu

clopidogrel

Known as: Clopidogrelum, clopidogrel [Chemical/Ingredient], methyl 2-(2-chlorophenyl)-2-(4,5,6,7-tetrahydrothieno(3,2-c)pyridin-5-yl)acetate 
a kind of anti-clotting drug
National Institutes of Health

Related topics

Related topics

21 relations
Blood Coagulation DisordersCerebral InfarctionCoronary ThrombosisDrug Allergy

Narrower (6)

Clopidogrel bisulfateIscoverPlavixSR 25989

Broader (4)

Platelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsThiopheneTiclopidine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
BACKGROUND The effect of intensified platelet inhibition for patients with unstable angina or myocardial infarction without ST… 
Highly Cited
2012
Highly Cited
2012
Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.
Highly Cited
2010
Highly Cited
2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
BACKGROUND Clopidogrel and aspirin are widely used for patients with acute coronary syndromes and those undergoing percutaneous… 
Highly Cited
2010
Highly Cited
2010
Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies: The RESPOND Study
Background— The antiplatelet effects of the Platelet Inhibition and Patient Outcomes (PLATO) trial dose of ticagrelor in patients… 
Highly Cited
2009
Highly Cited
2009
Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease: The ONSET/OFFSET Study
Background— Ticagrelor is the first reversibly binding oral P2Y12 receptor antagonist. This is the first study to compare the… 
Highly Cited
2008
Highly Cited
2008
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
BACKGROUND Recurrent stroke is a frequent, disabling event after ischemic stroke. This study compared the efficacy and safety of… 
Highly Cited
2006
Highly Cited
2006
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
CONTEXT No specifically designed studies have addressed the role of the glycoprotein IIb/IIIa inhibitor abciximab in patients… 
Highly Cited
2005
Highly Cited
2005
Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose…
Background— For patients undergoing percutaneous coronary intervention, the administration of a clopidogrel loading dose ranging… 
Highly Cited
2000
Highly Cited
2000
Identification and Biological Activity of the Active Metabolite of Clopidogrel
Summary Like ticlopidine, the ADP receptor antagonist clopidogrel is inactive in vitro and must be administered i.v. or orally to… 
Highly Cited
2000
Highly Cited
2000
Thrombotic thrombocytopenic purpura associated with clopidogrel.
BACKGROUND The antiplatelet drug clopidogrel is a new thienopyridine derivative whose mechanism of action and chemical structure… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)